Terminal state adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From June 2004 to June 2026, FDA received 6,621 adverse event reports that record the MedDRA preferred term Terminal state. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 269 reports in the 12 months to June 2026 and 336 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,266 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 269 (under 0.1%) record this term. Reports for male patients were 53.3% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 127 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Terminal state name as a suspect product, in order of name
Drug	Class	Reports with this term
Aclasta		61
Actemra	Interleukin-6 receptor antagonist	174
Adcirca	Phosphodiesterase 5 inhibitor	16
Advair Diskus	Corticosteroid	10
Afinitor	Kinase inhibitor	57
Albuterol sulfate	beta2-Adrenergic agonist	11
Ambien	gamma-Aminobutyric acid A receptor positive modulator	12
Ambrisentan	Endothelin receptor antagonist	116
Anakinra	Interleukin-1 receptor antagonist	147
Apo Leflunomide		17
Apo-Leflunomide		39
Aranesp	Erythropoiesis-stimulating agent	311
Arava	Antirheumatic agent	119
Avandia		14
Avonex	Interferon beta	19
Breo Ellipta	Corticosteroid	10
Cabometyx	Kinase inhibitor	32
Calcium Carbonate Cholecalciferol		14
Cannabis Sativa		45
Cannabis Sativa Flowering Top		30
Cannabis Sativa Subsp Indica Top		12
Carbidopa levodopa	Aromatic amino acid	165
Citalopram	Serotonin reuptake inhibitor	16
Clozapine	Atypical antipsychotic	37
Clozaril	Atypical antipsychotic	213
Creon		29
Dexamethasone	Corticosteroid	14
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose		25
Digoxin	Cardiac glycoside	10
Doxycycline	Tetracycline-class drug	10
Doxycycline hyclate	Tetracycline-class drug	16
Duodopa		121
Duopa	Aromatic amino acid	23
Eligard	Gonadotropin releasing hormone receptor agonist	587
Enbrel	Tumor necrosis factor blocker	206
Entresto	Angiotensin 2 receptor blocker	12
Esbriet	Pyridone	12
Exelon	Cholinesterase inhibitor	17
Exjade	Iron chelator	38
Forteo	Parathyroid hormone analog	17
Foscarbidopa/foslevodopa		26
Gleevec	Kinase inhibitor	14
Glivec		19
Gold	Standardized chemical allergen	129
Gold Sodium Thiomalate		45
Humira		251
Hydroxychloroquine	Antimalarial	126
Hydroxychloroquine sulfate	Antimalarial	97
Ibrance	Kinase inhibitor	15
Ilaris		112
Imbruvica	Kinase inhibitor	11
Jakafi	Janus kinase inhibitor	61
Keytruda	Programmed death Receptor-1 blocking antibody	23
Kisqali	Kinase inhibitor	14
Lanreotide acetate	Somatostatin analog	20
Leflunomide	Antirheumatic agent	129
Letairis	Endothelin receptor antagonist	19
Levetiracetam		14
Levothyroxine		14
Lonsurf	Nucleoside analog antiviral	12
Lucrin		24
Lucrin Depot		49
Lupron Depot		41
Lyrica		10
Marijuana		31
Mekinist	Kinase inhibitor	12
Melatonin		10
Mepolizumab	Interleukin-5 antagonist	11
Methotrexate	Folate analog metabolic inhibitor	162
Methotrexate sodium	Folate analog metabolic inhibitor	45
Minocycline	Tetracycline-class drug	67
Minocycline hydrochloride	Tetracycline-class drug	79
Morphine	Opioid agonist	19
Neulasta	Leukocyte growth factor	34
Nexavar	Kinase inhibitor	10
Nexium	Proton pump inhibitor	13
Northera		26
Nuplazid	Atypical antipsychotic	174
Octreotide acetate	Somatostatin analog	17
Ofev	Kinase inhibitor	14
Omeprazole	Proton pump inhibitor	14
Ondansetron	Serotonin-3 receptor antagonist	16
Opsumit	Endothelin receptor antagonist	96
Orencia	Selective T cell costimulation modulator	176
Oxycodone	Opioid agonist	82
Oxycodone hydrochloride	Opioid agonist	32
Plaquenil	Antimalarial	90
Prednisolone	Corticosteroid	24
Prednisone	Corticosteroid	13
Prolia	RANK ligand inhibitor	55
Remicade	Tumor necrosis factor blocker	177
Remodulin	Prostacycline vasodilator	46
Revatio	Phosphodiesterase 5 inhibitor	27
Revlimid	Thalidomide analog	30
Rinvoq	Janus kinase inhibitor	10
Rituxan	CD20-directed cytolytic antibody	79
Rituximab	CD20-directed cytolytic antibody	138
Sandostatin	Somatostatin analog	41
Sandostatin Lar		91
Sandostatin LAR Depot		183
Sandostatine Lar		16
Skyrizi	Interleukin-23 antagonist	11
Sodium Aurothiomalate		91
Soliris	Complement inhibitor	23
Somatuline Autogel		12
Stivarga	Kinase inhibitor	14
Sulfasalazine	Aminosalicylate	169
Tafinlar	Kinase inhibitor	14
Tecfidera		13
Tiotropium bromide	Anticholinergic	11
Tracleer	Endothelin receptor antagonist	77
Triptorelin pamoate		74
Tysabri	Integrin receptor antagonist	10
Tyvaso	Prostacycline vasodilator	22
Uptravi	Prostacyclin receptor agonist	37
Vedolizumab	Integrin receptor antagonist	22
Veletri	Prostacycline vasodilator	19
Venclexta	BCL-2 inhibitor	22
Ventolin Hfa	beta2-Adrenergic agonist	13
Votrient	Kinase inhibitor	23
Xeljanz	Janus kinase inhibitor	86
Xgeva	RANK ligand inhibitor	547
Xifaxan	Rifamycin antibacterial	21
Xtandi	Androgen receptor inhibitor	56
Zejula	Poly(ADP-Ribose) polymerase inhibitor	10
Zoladex	Gonadotropin releasing hormone receptor agonist	20
Zometa		435

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 35 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Terminal state name, in order of name
Class	Reports with this term
Aminosalicylate	169
Androgen receptor inhibitor	61
Angiotensin 2 receptor blocker	26
Antimalarial	313
Antirheumatic agent	248
Aromatic amino acid	188
Atypical antipsychotic	439
beta2-Adrenergic agonist	30
CD20-directed cytolytic antibody	217
Complement inhibitor	25
Corticosteroid	91
Endothelin receptor antagonist	312
Erythropoiesis-stimulating agent	313
Folate analog metabolic inhibitor	207
Gonadotropin releasing hormone receptor agonist	613
Integrin receptor antagonist	32
Interleukin-1 receptor antagonist	149
Interleukin-6 receptor antagonist	180
Iron chelator	40
Janus kinase inhibitor	164
Kinase inhibitor	270
Leukocyte growth factor	34
Opioid agonist	148
Phosphodiesterase 5 inhibitor	50
Programmed death Receptor-1 blocking antibody	29
Prostacyclin receptor agonist	37
Prostacycline vasodilator	105
Proton pump inhibitor	39
RANK ligand inhibitor	602
Selective T cell costimulation modulator	176
Somatostatin analog	85
Standardized chemical allergen	129
Tetracycline-class drug	172
Thalidomide analog	42
Tumor necrosis factor blocker	407

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Terminal state, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Terminal state
Age	Reports	Share
Under 2	4	0.1%
2 to 11	13	0.2%
12 to 17	11	0.2%
18 to 44	168	2.5%
45 to 64	947	14.3%
65 to 74	799	12.1%
75 and over	1,209	18.3%
Age not given	3,470	52.4%

Sex of the patient in the reports that record Terminal state
Sex	Reports	Share
Female	2,631	39.7%
Male	3,532	53.3%
Unknown or not given	458	6.9%

Age and sex are as the report gives them. 33.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Terminal state: adverse event reports that record this term. https://reportedreactions.com/reaction/terminal-state/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Terminal state mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page